This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Centene Continues to Capitalize on Obamacare and So Will You

NEW YORK (TheStreet) -- Centene (CNC - Get Report) is in the health care sweetspot thanks to being part of one of the leading industry groups this year, health care providers.

Centene shares, at $80, are up 35% for the year to date.

Concerns about the launch of the Affordable Care Act, aka Obamacare, sent these stocks into a tailspin at first, but most of these stocks have since regained ground over the last few months as investors realize the growth potential.

Read More: The Story Behind Sarepta's Firing of Its Top Scientist

There continues to be conflicting court rulings surrounding the legality of Obamacare subsidies, but in the absence of a U.S. Supreme Court decision, the provider stocks appear to be shrugging off these lower court rulings.

Data from Best Stocks Now App

Centene provides programs and related services to address the needs of the under-insured and uninsured individuals. It offers Medicaid and Medicaid-related coverage to individuals through government subsidized programs and operates in 21 states.

As a result of the Affordable Care Act, an additional six million Americans have enrolled in Medicaid and related health programs for the poor through the end of April. More people are now eligible for state Medicaid programs and many of these states are expanding their programs and contracting with private health insurance companies like Molina (MOH), Health Net (HNT) and Centene. Medicaid is now a growth story and these companies are the beneficiaries.

Earnings Results

On Tuesday, Centene reported strong second-quarter earnings results of 95 cents vs. the consensus of 72 cents. Revenue of $3.74 billion also beat the consensus estimate of $3.65 billion. The company guided up this year's earnings to a range of $3.70-$3.90 vs. prior guidance of $3.60-$3.90 and the consensus of $3.73.

Read More: Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CNC $70.69 -0.76%
AAPL $124.43 -1.54%
FB $82.22 -1.18%
GOOG $548.00 -0.73%
TSLA $188.77 -0.94%


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs